Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Triage Profiler S.O.B. Panel · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Control-Blinded from Results | NO_INTERVENTION | - |
| Access to Results | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Triage Profiler S.O.B. Panel | DEVICE | - |
Inclusion Criteria: * Age 18 and older. * Visit to the ED is due to a primary complaint of shortness of breath alone or shortness of breath with associated chest pain, cough or edema. Exclusion Criteria: * Blood sample cannot be collected before treatment is initiated, specifically CPR or treatme...
The Triage Profiler S.O.B. Panel is an investigational diagnostic tool being studied for use in Acute Myocardial Infarction, as well as Heart Failure and Pulmonary Embolism. It is intended to aid in the evaluation of patients presenting with shortness of breath in the emergency department setting.
Abbott Laboratories (NYSE: ABT) is the developer of the Triage Profiler S.O.B. Panel. The company is conducting clinical research on this diagnostic panel for cardiovascular conditions.
The Triage Profiler S.O.B. Panel is in Phase 2 clinical development. It is an investigational product and has not been approved by regulatory authorities. One Phase 2 trial has been completed.
The Triage Profiler S.O.B. Panel was studied in the SHORTness of Breath In the Emergency Department (SHORTIE) trial, registered as NCT00206830. This Phase 2, randomized, double-blind, no-treatment-controlled study enrolled 306 participants in the United States and has been completed.
The Triage Profiler S.O.B. Panel is not FDA approved. It is an investigational diagnostic currently in Phase 2 clinical development. The completed trial, NCT00206830, evaluated its use in patients with acute myocardial infarction, heart failure, and pulmonary embolism.